Blinatumomab, a bispecific antibody against CD3 and CD19, allows CD3-expressing T cells to kill CD19-expressing B cell precursors and improves survival in relapsed or refractory acute lymphoblastic leukemia (30). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.